{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:10:58Z","timestamp":1765357858893,"version":"3.41.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"PRIN 2022 PNRR, Ministero Universit\u00e0 e Ricerca","award":["P2022LZXNW"],"award-info":[{"award-number":["P2022LZXNW"]}]},{"name":"Progetti di Ateneo Sapienza","award":["RM12218166C5057A"],"award-info":[{"award-number":["RM12218166C5057A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-025-00668-1","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T16:16:00Z","timestamp":1751472960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vitro synergistic effect of AXL, FAK and ErbB receptors inhibitors for head and neck cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Valeria","family":"Lucarini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Angiolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Nardozi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Benvenuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Focaccetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Splendiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja Milena","family":"Autilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Bei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Cifaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Masuelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"9625","key":"668_CR1","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","volume":"371","author":"A Argiris","year":"2008","unstructured":"Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695\u2013709. https:\/\/doi.org\/10.1016\/S0140-6736(08)60728-X.","journal-title":"Lancet"},{"key":"668_CR2","doi-asserted-by":"publisher","first-page":"1066021","DOI":"10.3389\/fmed.2023.1066021","volume":"10","author":"C Palumbo","year":"2023","unstructured":"Palumbo C, Benvenuto M, Focaccetti C, Albonici L, Cifaldi L, Rufini A, et al. Recent findings on the impact of erbb receptors status on prognosis and therapy of head and neck squamous cell carcinoma. Front Med (Lausanne). 2023;10:1066021. https:\/\/doi.org\/10.3389\/fmed.2023.1066021.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"668_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13062-024-00573-z","volume":"19","author":"S Chen","year":"2024","unstructured":"Chen S, Wu K, Zong Y, Hou Z, Deng Z, Xia Z. USP44 regulates HEXIM1 stability to inhibit tumorigenesis and metastasis of oral squamous cell carcinoma. Biol Direct. 2024;19(1):143. https:\/\/doi.org\/10.1186\/s13062-024-00573-z.","journal-title":"Biol Direct"},{"issue":"1","key":"668_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13062-023-00426-1","volume":"18","author":"A Cappello","year":"2023","unstructured":"Cappello A, Tosetti G, Smirnov A, Ganini C, Yang X, Shi Y, et al. p63 orchestrates Serine and one carbon metabolism enzymes expression in head and neck cancer. Biol Direct. 2023;18(1):73. https:\/\/doi.org\/10.1186\/s13062-023-00426-1.","journal-title":"Biol Direct"},{"issue":"5","key":"668_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41418-024-01285-7","volume":"31","author":"X Jin","year":"2024","unstructured":"Jin X, Liu L, Liu D, Wu J, Wang C, Wang S, et al. Unveiling the methionine cycle: a key metabolic signature and NR4A2 as a methionine-responsive oncogene in esophageal squamous cell carcinoma. Cell Death Differ. 2024;31(5):558\u201373. https:\/\/doi.org\/10.1038\/s41418-024-01285-7.","journal-title":"Cell Death Differ"},{"key":"668_CR6","doi-asserted-by":"publisher","unstructured":"Ciani L, Libonati A, Dri M, Pomella S, Campanella V, Barillari G. About a possible impact of endodontic infections by Fusobacterium nucleatum or Porphyromonas gingivalis on oral carcinogenesis: A literature overview. Int J Mol Sci. 2024;25(10). https:\/\/doi.org\/10.3390\/ijms25105083.","DOI":"10.3390\/ijms25105083"},{"issue":"4","key":"668_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41418-024-01272-y","volume":"31","author":"E Sanz-Garcia","year":"2024","unstructured":"Sanz-Garcia E, Zou J, Avery L, Spreafico A, Waldron J, Goldstein D, et al. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck. Cell Death Differ. 2024;31(4):460\u20138. https:\/\/doi.org\/10.1038\/s41418-024-01272-y.","journal-title":"Cell Death Differ"},{"issue":"3","key":"668_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41418-024-01257-x","volume":"31","author":"B Zhang","year":"2024","unstructured":"Zhang B, Li J, Wang Y, Liu X, Yang X, Liao Z, et al. Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16\/TOP2A axis. Cell Death Differ. 2024;31(3):309\u201321. https:\/\/doi.org\/10.1038\/s41418-024-01257-x.","journal-title":"Cell Death Differ"},{"key":"668_CR9","doi-asserted-by":"publisher","unstructured":"Kleszcz R. Advantages of the combinatorial molecular targeted therapy of head and neck Cancer-A step before Anakoinosis-Based personalized treatment. Cancers (Basel). 2023;15(17). https:\/\/doi.org\/10.3390\/cancers15174247.","DOI":"10.3390\/cancers15174247"},{"key":"668_CR10","doi-asserted-by":"publisher","first-page":"175883592094941","DOI":"10.1177\/1758835920949418","volume":"13","author":"M Fasano","year":"2021","unstructured":"Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, et al. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol. 2021;13:1758835920949418. https:\/\/doi.org\/10.1177\/1758835920949418.","journal-title":"Ther Adv Med Oncol"},{"issue":"20","key":"668_CR11","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.2174\/1871520622666220408090541","volume":"22","author":"A Unnisa","year":"2022","unstructured":"Unnisa A, Chettupalli AK, Hussain T, Kamal MA. Recent advances in epidermal growth factor receptor inhibitors (EGFRIs) and their role in the treatment of cancer: A review. Anticancer Agents Med Chem. 2022;22(20):3370\u201381. https:\/\/doi.org\/10.2174\/1871520622666220408090541.","journal-title":"Anticancer Agents Med Chem"},{"key":"668_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","volume":"139","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski R Jr. Small molecule inhibitors targeting the egfr\/erbb family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019;139:395\u2013411. https:\/\/doi.org\/10.1016\/j.phrs.2018.11.014.","journal-title":"Pharmacol Res"},{"key":"668_CR13","doi-asserted-by":"publisher","unstructured":"He Y, Zeng J, Wei Z, Huang Y, Yang L, Hu X, et al. Comparison of Second-Line treatments for patients with Platinum-Resistant recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and bayesian network Meta-Analysis. Cancers (Basel). 2022;14(18). https:\/\/doi.org\/10.3390\/cancers14184472.","DOI":"10.3390\/cancers14184472"},{"issue":"1","key":"668_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12885-022-10428-3","volume":"23","author":"Y Harada","year":"2023","unstructured":"Harada Y, Sato A, Nakamura H, Kai K, Kitamura S, Nakamura T, et al. Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer. BMC Cancer. 2023;23(1):77. https:\/\/doi.org\/10.1186\/s12885-022-10428-3.","journal-title":"BMC Cancer"},{"issue":"3","key":"668_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.radonc.2011.06.006","volume":"99","author":"I Eke","year":"2011","unstructured":"Eke I, Cordes N. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. Radiother Oncol. 2011;99(3):279\u201386. https:\/\/doi.org\/10.1016\/j.radonc.2011.06.006.","journal-title":"Radiother Oncol"},{"issue":"39","key":"668_CR16","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1038\/s41388-023-02810-7","volume":"42","author":"K Okamoto","year":"2023","unstructured":"Okamoto K, Ando T, Izumi H, Kobayashi SS, Shintani T, Gutkind JS, et al. AXL activates YAP through the EGFR-LATS1\/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma. Oncogene. 2023;42(39):2869\u201377. https:\/\/doi.org\/10.1038\/s41388-023-02810-7.","journal-title":"Oncogene"},{"key":"668_CR17","doi-asserted-by":"publisher","unstructured":"Diniz CHP, Henrique T, Stefanini ACB, De Castro TB, Tajara EH. Cetuximab chemotherapy resistance: insight into the homeostatic evolution of head and neck cancer (Review). Oncol Rep. 2024;51(6). https:\/\/doi.org\/10.3892\/or.2024.8739.","DOI":"10.3892\/or.2024.8739"},{"issue":"1","key":"668_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12885-022-09511-6","volume":"22","author":"M Iida","year":"2022","unstructured":"Iida M, McDaniel NK, Kostecki KL, Welke NB, Kranjac CA, Liu P, et al. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022;22(1):447. https:\/\/doi.org\/10.1186\/s12885-022-09511-6.","journal-title":"BMC Cancer"},{"issue":"2","key":"668_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00280-017-3239-3","volume":"79","author":"H Liebig","year":"2017","unstructured":"Liebig H, Gunther G, Kolb M, Mozet C, Boehm A, Dietz A, et al. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and Hedgehog pathways. Cancer Chemother Pharmacol. 2017;79(2):411\u201320. https:\/\/doi.org\/10.1007\/s00280-017-3239-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"668_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18(1):153. https:\/\/doi.org\/10.1186\/s12943-019-1090-3.","journal-title":"Mol Cancer"},{"key":"668_CR21","doi-asserted-by":"publisher","unstructured":"Nieto MA. Epithelial-Mesenchymal transitions in development and disease: old views and new perspectives. Int J Dev Biol. 2009;53(8\u201310):1541\u20137. https:\/\/doi.org\/10.1387\/ijdb.072410mn.","DOI":"10.1387\/ijdb.072410mn"},{"issue":"1","key":"668_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19(1):279\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1558.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"668_CR23","doi-asserted-by":"publisher","first-page":"eabk2746","DOI":"10.1126\/sciadv.abk2746","volume":"8","author":"A Adam-Artigues","year":"2022","unstructured":"Adam-Artigues A, Arenas EJ, Martinez-Sabadell A, Braso-Maristany F, Cervera R, Tormo E, et al. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 Blockade in breast cancer. Sci Adv. 2022;8(20):eabk2746. https:\/\/doi.org\/10.1126\/sciadv.abk2746.","journal-title":"Sci Adv"},{"key":"668_CR24","doi-asserted-by":"publisher","unstructured":"Busch CJ, Hagel C, Becker B, Oetting A, Mockelmann N, Droste C, et al. Tissue microarray analyses suggest Axl as a predictive biomarker in HPV-Negative head and neck Cancer. Cancers (Basel). 2022;14(7). https:\/\/doi.org\/10.3390\/cancers14071829.","DOI":"10.3390\/cancers14071829"},{"key":"668_CR25","doi-asserted-by":"publisher","first-page":"811247","DOI":"10.3389\/fonc.2022.811247","volume":"12","author":"YB Sang","year":"2022","unstructured":"Sang YB, Kim JH, Kim CG, Hong MH, Kim HR, Cho BC, et al. The development of AXL inhibitors in lung cancer: recent progress and challenges. Front Oncol. 2022;12:811247. https:\/\/doi.org\/10.3389\/fonc.2022.811247.","journal-title":"Front Oncol"},{"key":"668_CR26","doi-asserted-by":"publisher","unstructured":"Worthmuller J, Ruegg C. The crosstalk between FAK and Wnt signaling pathways in Cancer and its therapeutic implication. Int J Mol Sci. 2020;21(23). https:\/\/doi.org\/10.3390\/ijms21239107.","DOI":"10.3390\/ijms21239107"},{"issue":"1","key":"668_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-23-0964","volume":"30","author":"PM Pifer","year":"2024","unstructured":"Pifer PM, Yang L, Kumar M, Xie T, Frederick M, Hefner A, et al. FAK drives resistance to therapy in HPV-Negative head and neck Cancer in a p53-Dependent manner. Clin Cancer Res. 2024;30(1):187\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0964.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"668_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13045-020-01009-7","volume":"13","author":"Y Fu","year":"2020","unstructured":"Fu Y, Zhang Y, Lei Z, Liu T, Cai T, Wang A, et al. Abnormally activated opn\/integrin alphaVbeta3\/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol. 2020;13(1):169. https:\/\/doi.org\/10.1186\/s13045-020-01009-7.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"668_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","volume":"21","author":"JC Dawson","year":"2021","unstructured":"Dawson JC, Serrels A, Stupack DG, Schlaepfer DD, Frame MC. Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021;21(5):313\u201324. https:\/\/doi.org\/10.1038\/s41568-021-00340-6.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"668_CR30","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/1535-7163.MCT-16-0366","volume":"15","author":"TA Marlowe","year":"2016","unstructured":"Marlowe TA, Lenzo FL, Figel SA, Grapes AT, Cance WG. Oncogenic receptor tyrosine kinases directly phosphorylate focal adhesion kinase (FAK) as a resistance mechanism to FAK-Kinase inhibitors. Mol Cancer Ther. 2016;15(12):3028\u201339. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0366.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"668_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s11033-025-10296-7","volume":"52","author":"J Aakriti","year":"2025","unstructured":"Aakriti J, Vithalkar MP, Maity S, Baby K, Nagareddy PR, Nayak Y. Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumors. Mol Biol Rep. 2025;52(1):248. https:\/\/doi.org\/10.1007\/s11033-025-10296-7.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"668_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/bjc.2016.190","volume":"115","author":"H Zhang","year":"2016","unstructured":"Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA, et al. Efficacy of focal adhesion kinase Inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. Br J Cancer. 2016;115(2):203\u201311. https:\/\/doi.org\/10.1038\/bjc.2016.190.","journal-title":"Br J Cancer"},{"key":"668_CR33","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1017\/erm.2020.4","volume":"22","author":"C Zhou","year":"2020","unstructured":"Zhou C, Parsons JL. The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma. Expert Rev Mol Med. 2020;22:e3. https:\/\/doi.org\/10.1017\/erm.2020.4.","journal-title":"Expert Rev Mol Med"},{"issue":"1","key":"668_CR34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12967-022-03490-9","volume":"20","author":"R Bei","year":"2022","unstructured":"Bei R, Benvenuto M, Focaccetti C, Fazi S, Moretti M, Nardozi D, et al. Combined treatment with inhibitors of erbb receptors and hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo. J Transl Med. 2022;20(1):286. https:\/\/doi.org\/10.1186\/s12967-022-03490-9.","journal-title":"J Transl Med"},{"issue":"8","key":"668_CR35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00262-010-0850-0","volume":"59","author":"L Masuelli","year":"2010","unstructured":"Masuelli L, Marzocchella L, Focaccetti C, Lista F, Nardi A, Scardino A, et al. Local delivery of Recombinant vaccinia virus encoding for Neu counteracts growth of mammary tumors more efficiently than systemic delivery in Neu Transgenic mice. Cancer Immunol Immunother. 2010;59(8):1247\u201358. https:\/\/doi.org\/10.1007\/s00262-010-0850-0.","journal-title":"Cancer Immunol Immunother"},{"key":"668_CR36","doi-asserted-by":"publisher","unstructured":"Arena A, Romeo MA, Benedetti R, Masuelli L, Bei R, Gilardini Montani MS, et al. New insights into Curcumin- and Resveratrol-Mediated Anti-Cancer effects. Pharmaceuticals (Basel). 2021;14(11). https:\/\/doi.org\/10.3390\/ph14111068.","DOI":"10.3390\/ph14111068"},{"issue":"2","key":"668_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3892\/ijo.30.2.381","volume":"30","author":"L Masuelli","year":"2007","unstructured":"Masuelli L, Focaccetti C, Cereda V, Lista F, Vitolo D, Trono P, et al. Gene-specific Inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human erbb receptors. Int J Oncol. 2007;30(2):381\u201392. https:\/\/doi.org\/10.3892\/ijo.30.2.381.","journal-title":"Int J Oncol"},{"issue":"5","key":"668_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.4161\/cam.36224","volume":"8","author":"JE Jonkman","year":"2014","unstructured":"Jonkman JE, Cathcart JA, Xu F, Bartolini ME, Amon JE, Stevens KM, et al. An introduction to the wound healing assay using live-cell microscopy. Cell Adh Migr. 2014;8(5):440\u201351. https:\/\/doi.org\/10.4161\/cam.36224.","journal-title":"Cell Adh Migr"},{"issue":"9","key":"668_CR39","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/jcp.24034","volume":"227","author":"L Masuelli","year":"2012","unstructured":"Masuelli L, Budillon A, Marzocchella L, Mrozek MA, Vitolo D, Di Gennaro E, et al. Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin\/alpha-beta catenins complex and multiple erbb receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. J Cell Physiol. 2012;227(9):3344\u201353. https:\/\/doi.org\/10.1002\/jcp.24034.","journal-title":"J Cell Physiol"},{"issue":"7","key":"668_CR40","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/s41418-023-01171-8","volume":"30","author":"P Wu","year":"2023","unstructured":"Wu P, Hou X, Peng M, Deng X, Yan Q, Fan C, et al. Circular RNA circRILPL1 promotes nasopharyngeal carcinoma malignant progression by activating the Hippo-YAP signaling pathway. Cell Death Differ. 2023;30(7):1679\u201394. https:\/\/doi.org\/10.1038\/s41418-023-01171-8.","journal-title":"Cell Death Differ"},{"issue":"7","key":"668_CR41","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1080\/09637486.2023.2251723","volume":"74","author":"M Benvenuto","year":"2023","unstructured":"Benvenuto M, Nardozi D, Palumbo C, Focaccetti C, Carrano R, Angiolini V, et al. Curcumin potentiates the erbb receptors inhibitor Afatinib for enhanced antitumor activity in malignant mesothelioma. Int J Food Sci Nutr. 2023;74(7):746\u201359. https:\/\/doi.org\/10.1080\/09637486.2023.2251723.","journal-title":"Int J Food Sci Nutr"},{"key":"668_CR42","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejphar.2017.11.016","volume":"818","author":"S Aveic","year":"2018","unstructured":"Aveic S, Corallo D, Porcu E, Pantile M, Boso D, Zanon C, et al. TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy. Eur J Pharmacol. 2018;818:435\u201348. https:\/\/doi.org\/10.1016\/j.ejphar.2017.11.016.","journal-title":"Eur J Pharmacol"},{"key":"668_CR43","doi-asserted-by":"publisher","unstructured":"Enserink JM, Chymkowitch P. Cell Cycle-Dependent transcription: the Cyclin dependent kinase Cdk1 is a direct regulator of basal transcription machineries. Int J Mol Sci. 2022;23(3). https:\/\/doi.org\/10.3390\/ijms23031293.","DOI":"10.3390\/ijms23031293"},{"issue":"11","key":"668_CR44","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/s41416-023-02468-8","volume":"129","author":"G Massacci","year":"2023","unstructured":"Massacci G, Perfetto L, Sacco F. The Cyclin-dependent kinase 1: more than a cell cycle regulator. Br J Cancer. 2023;129(11):1707\u201316. https:\/\/doi.org\/10.1038\/s41416-023-02468-8.","journal-title":"Br J Cancer"},{"issue":"2","key":"668_CR45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jconrel.2012.04.045","volume":"164","author":"G Mehta","year":"2012","unstructured":"Mehta G, Hsiao AY, Ingram M, Luker GD, Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release. 2012;164(2):192\u2013204. https:\/\/doi.org\/10.1016\/j.jconrel.2012.04.045.","journal-title":"J Control Release"},{"key":"668_CR46","doi-asserted-by":"publisher","first-page":"19103","DOI":"10.1038\/srep19103","volume":"6","author":"M Zanoni","year":"2016","unstructured":"Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016;6:19103. https:\/\/doi.org\/10.1038\/srep19103.","journal-title":"Sci Rep"},{"key":"668_CR47","doi-asserted-by":"publisher","unstructured":"Costantini E, Aielli L, Serra F, De Dominicis L, Falasca K, Di Giovanni P, et al. Evaluation of cell migration and cytokines expression changes under the radiofrequency electromagnetic field on wound healing in vitro model. Int J Mol Sci. 2022;23(4). https:\/\/doi.org\/10.3390\/ijms23042205.","DOI":"10.3390\/ijms23042205"},{"key":"668_CR48","doi-asserted-by":"publisher","unstructured":"Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci. 2021;22(11). https:\/\/doi.org\/10.3390\/ijms22115703.","DOI":"10.3390\/ijms22115703"},{"key":"668_CR49","doi-asserted-by":"publisher","unstructured":"Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, et al. The E-Cadherin and N-Cadherin switch in Epithelial-to-Mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10). https:\/\/doi.org\/10.3390\/cells8101118.","DOI":"10.3390\/cells8101118"},{"key":"668_CR50","doi-asserted-by":"publisher","unstructured":"Usman S, Waseem NH, Nguyen TKN, Mohsin S, Jamal A, Teh MT, et al. Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers (Basel). 2021;13(19). https:\/\/doi.org\/10.3390\/cancers13194985.","DOI":"10.3390\/cancers13194985"},{"key":"668_CR51","doi-asserted-by":"publisher","unstructured":"Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A, Amini A. An updated review on head and neck Cancer treatment with radiation therapy. Cancers (Basel). 2021;13(19). https:\/\/doi.org\/10.3390\/cancers13194912.","DOI":"10.3390\/cancers13194912"},{"issue":"1","key":"668_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13062-024-00499-6","volume":"19","author":"Y Liang","year":"2024","unstructured":"Liang Y, Zhong H, Zhao Y, Tang X, Pan C, Sun J, et al. Epigenetic mechanism of RBM15 in affecting cisplatin resistance in laryngeal carcinoma cells by regulating ferroptosis. Biol Direct. 2024;19(1):57. https:\/\/doi.org\/10.1186\/s13062-024-00499-6.","journal-title":"Biol Direct"},{"issue":"5","key":"668_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41418-024-01287-5","volume":"31","author":"P Feng","year":"2024","unstructured":"Feng P, Wang Y, Liu N, Chen Y, Hu Y, Huang Z, et al. High expression of PPP1CC promotes NHEJ-mediated DNA repair leading to radioresistance and poor prognosis in nasopharyngeal carcinoma. Cell Death Differ. 2024;31(5):683\u201396. https:\/\/doi.org\/10.1038\/s41418-024-01287-5.","journal-title":"Cell Death Differ"},{"key":"668_CR54","doi-asserted-by":"publisher","first-page":"101426","DOI":"10.1016\/j.tranon.2022.101426","volume":"21","author":"B Goel","year":"2022","unstructured":"Goel B, Tiwari AK, Pandey RK, Singh AP, Kumar S, Sinha A, et al. Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials. Transl Oncol. 2022;21:101426. https:\/\/doi.org\/10.1016\/j.tranon.2022.101426.","journal-title":"Transl Oncol"},{"issue":"1","key":"668_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther. 2023;8(1):31. https:\/\/doi.org\/10.1038\/s41392-022-01297-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"668_CR56","doi-asserted-by":"publisher","first-page":"103852","DOI":"10.1016\/j.drudis.2023.103852","volume":"29","author":"P Prasad","year":"2024","unstructured":"Prasad P, Billah Khair AM, Venkatesan K, Shahwan M, Shamsi A. Molecular and functional insight into focal adhesion kinases: therapeutic implications for oral malignancies. Drug Discov Today. 2024;29(1):103852. https:\/\/doi.org\/10.1016\/j.drudis.2023.103852.","journal-title":"Drug Discov Today"},{"issue":"5","key":"668_CR57","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41418-023-01153-w","volume":"30","author":"I Vitale","year":"2023","unstructured":"Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease-Current Understanding of the NCCD 2023. Cell Death Differ. 2023;30(5):1097\u2013154. https:\/\/doi.org\/10.1038\/s41418-023-01153-w.","journal-title":"Cell Death Differ"},{"key":"668_CR58","doi-asserted-by":"publisher","first-page":"10207","DOI":"10.2147\/OTT.S270342","volume":"13","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Sun X. Role of focal adhesion kinase in head and neck squamous cell carcinoma and its therapeutic prospect. Onco Targets Ther. 2020;13:10207\u201320. https:\/\/doi.org\/10.2147\/OTT.S270342.","journal-title":"Onco Targets Ther"},{"key":"668_CR59","doi-asserted-by":"publisher","unstructured":"von Massenhausen A, Bragelmann J, Billig H, Thewes B, Queisser A, Vogel W, et al. Implication of the receptor tyrosine kinase AXL in head and neck Cancer progression. Int J Mol Sci. 2016;18(1). https:\/\/doi.org\/10.3390\/ijms18010007.","DOI":"10.3390\/ijms18010007"},{"key":"668_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41199-016-0020-y","volume":"2","author":"P Bossi","year":"2017","unstructured":"Bossi P, Platini F. Radiotherapy plus EGFR inhibitors: synergistic modalities. Cancers Head Neck. 2017;2:2. https:\/\/doi.org\/10.1186\/s41199-016-0020-y.","journal-title":"Cancers Head Neck"},{"issue":"4","key":"668_CR61","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ctrv.2013.10.002","volume":"40","author":"RB Cohen","year":"2014","unstructured":"Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and erbb family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev. 2014;40(4):567\u201377. https:\/\/doi.org\/10.1016\/j.ctrv.2013.10.002.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"668_CR62","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/ijc.28261","volume":"134","author":"F Li","year":"2014","unstructured":"Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer. 2014;134(6):1257\u201369. https:\/\/doi.org\/10.1002\/ijc.28261.","journal-title":"Int J Cancer"},{"key":"668_CR63","doi-asserted-by":"publisher","first-page":"101157","DOI":"10.1016\/j.neo.2025.101157","volume":"63","author":"DB Manikandan","year":"2025","unstructured":"Manikandan DB, Jagadeeshan S, Mathukkada S, Shareb RA, Prasad M, Belsamma LVS, et al. Anti-PD1 prolongs the response of PI3K and Farnesyl transferase Inhibition in HRAS- and PIK3CA-mutant head and neck cancers. Neoplasia. 2025;63:101157. https:\/\/doi.org\/10.1016\/j.neo.2025.101157.","journal-title":"Neoplasia"},{"key":"668_CR64","doi-asserted-by":"publisher","first-page":"217124","DOI":"10.1016\/j.canlet.2024.217124","volume":"598","author":"R Nakamura","year":"2024","unstructured":"Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, et al. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer Lett. 2024;598:217124. https:\/\/doi.org\/10.1016\/j.canlet.2024.217124.","journal-title":"Cancer Lett"},{"issue":"14","key":"668_CR65","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.22.01693","volume":"41","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, et al. ANCHOR CRC: results from a Single-Arm, phase II study of Encorafenib plus binimetinib and cetuximab in previously untreated BRAF(V600E)-Mutant metastatic colorectal Cancer. J Clin Oncol. 2023;41(14):2628\u201337. https:\/\/doi.org\/10.1200\/JCO.22.01693.","journal-title":"J Clin Oncol"},{"issue":"9","key":"668_CR66","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.xcrm.2024.101703","volume":"5","author":"A Simoni-Nieves","year":"2024","unstructured":"Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai BR, et al. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib. Cell Rep Med. 2024;5(9):101703. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101703.","journal-title":"Cell Rep Med"},{"key":"668_CR67","doi-asserted-by":"publisher","first-page":"106861","DOI":"10.1016\/j.oraloncology.2024.106861","volume":"154","author":"A Desilets","year":"2024","unstructured":"Desilets A, Pfister DG, Stein S, Wong W, Sherman EJ, Fetten J, et al. A phase 1 study of concurrent Cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. Oral Oncol. 2024;154:106861. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106861.","journal-title":"Oral Oncol"},{"issue":"1","key":"668_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-00994-y","volume":"31","author":"WH Abuwatfa","year":"2024","unstructured":"Abuwatfa WH, Pitt WG, Husseini GA. Scaffold-based 3D cell culture models in cancer research. J Biomed Sci. 2024;31(1):7. https:\/\/doi.org\/10.1186\/s12929-024-00994-y.","journal-title":"J Biomed Sci"},{"issue":"10","key":"668_CR69","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21(10):607\u201332. https:\/\/doi.org\/10.1038\/s41580-020-0255-7.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"668_CR70","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.3892\/etm.2020.8454","volume":"19","author":"YJ Guo","year":"2020","unstructured":"Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK\/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997\u20132007. https:\/\/doi.org\/10.3892\/etm.2020.8454.","journal-title":"Exp Ther Med"},{"issue":"1","key":"668_CR71","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13062-023-00396-4","volume":"18","author":"C Liu","year":"2023","unstructured":"Liu C, Li G, Zheng S, She L, Lu S, Wang Y, et al. PHF5A regulates the expression of the DOCK5 variant to promote HNSCC progression through p38 MAPK activation. Biol Direct. 2023;18(1):39. https:\/\/doi.org\/10.1186\/s13062-023-00396-4.","journal-title":"Biol Direct"},{"key":"668_CR72","doi-asserted-by":"publisher","unstructured":"Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5). https:\/\/doi.org\/10.3390\/cancers9050052.","DOI":"10.3390\/cancers9050052"},{"issue":"1","key":"668_CR73","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","volume":"8","author":"K Jacobsen","year":"2017","unstructured":"Jacobsen K, Bertran-Alamillo J, Molina MA, Teixido C, Karachaliou N, Pedersen MH, et al. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017;8(1):410. https:\/\/doi.org\/10.1038\/s41467-017-00450-6.","journal-title":"Nat Commun"},{"issue":"1","key":"668_CR74","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01634-6","volume":"18","author":"A Glaviano","year":"2025","unstructured":"Glaviano A, Lau HS, Carter LM, Lee EHC, Lam HY, Okina E, et al. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J Hematol Oncol. 2025;18(1):6. https:\/\/doi.org\/10.1186\/s13045-024-01634-6.","journal-title":"J Hematol Oncol"},{"key":"668_CR75","doi-asserted-by":"publisher","unstructured":"de Bakker T, Maes A, Dragan T, Martinive P, Penninckx S, Van Gestel D. Strategies to overcome intrinsic and acquired resistance to chemoradiotherapy in head and neck Cancer. Cells. 2024;14(1). https:\/\/doi.org\/10.3390\/cells14010018.","DOI":"10.3390\/cells14010018"},{"issue":"1","key":"668_CR76","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15(1):173. https:\/\/doi.org\/10.1186\/s13045-022-01391-4.","journal-title":"J Hematol Oncol"},{"key":"668_CR77","doi-asserted-by":"publisher","first-page":"102864","DOI":"10.1016\/j.ctrv.2024.102864","volume":"132","author":"X Tian","year":"2025","unstructured":"Tian X, Zhang H, Han Y, Gu B, Zhang Z. Current status and future prospects of combined immunotherapy and epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. Cancer Treat Rev. 2025;132:102864. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102864.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"668_CR78","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1038\/s41591-024-03161-w","volume":"30","author":"NF Saba","year":"2024","unstructured":"Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, et al. Author correction: pembrolizumab and Cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. Nat Med. 2024;30(8):2373. https:\/\/doi.org\/10.1038\/s41591-024-03161-w.","journal-title":"Nat Med"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-025-00668-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-025-00668-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-025-00668-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T16:16:01Z","timestamp":1751472961000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologydirect.biomedcentral.com\/articles\/10.1186\/s13062-025-00668-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1186\/s13062-025-00668-1","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}